• 主页
  • 查找结果
  • Efficacy of sonazoid (perflubutane) for contrast-enhanced ultrasound in the differentiation of focal breast lesions: phase 3 multicenter clinical trial.

Efficacy of sonazoid (perflubutane) for contrast-enhanced ultrasound in the differentiation of focal breast lesions: phase 3 multicenter clinical trial.

AJR. American journal of roentgenology (2014-03-26)
Yukio Miyamoto, Toshikazu Ito, Etsuo Takada, Kiyoka Omoto, Toshiko Hirai, Fuminori Moriyasu
摘要

The objective of our study was to compare the efficacy of contrast-enhanced ultrasound (CEUS) using the ultrasound contrast agent Sonazoid (perflubutane) with unenhanced ultrasound and supplementary contrast-enhanced MRI in the differential diagnosis (benign vs malignant) of focal breast lesions. The safety of Sonazoid was also assessed in this study. A total of 127 patients with focal breast lesions were enrolled in this study at five centers in Japan. Three reviewers who were blinded to the patient characteristics independently assessed the ultrasound images and MR images in a randomized sequence. The accuracy, sensitivity, and specificity of CEUS, unenhanced ultrasound, and supplementary contrast-enhanced MRI for the differential diagnosis were compared using generalized estimating equation analyses. Diagnostic confidence was also assessed. The accuracy of CEUS was significantly higher than that of unenhanced ultrasound (87.2% vs 65.5%, respectively; p < 0.001). In addition, CEUS showed significantly higher specificity, although the improvement in sensitivity was not statistically significant. The accuracy and specificity were significantly higher with CEUS than with contrast-enhanced MRI, but the improvement in sensitivity was not statistically significant. The area under the curve in a receiver operating characteristic analysis was significantly greater with CEUS than with unenhanced ultrasound. The incidence of adverse events was 11.4% and the incidence of adverse drug reactions was 3.3%. All adverse drug reactions were mild. CEUS using Sonazoid was confirmed to be superior to unenhanced ultrasound for the differential diagnosis (benign vs malignant) of focal breast lesions in terms of diagnostic accuracy with no serious adverse reactions.

材料
货号
品牌
产品描述

Sigma-Aldrich
铁, ≥99%, reduced, powder (fine)
Sigma-Aldrich
N -甲基- D -葡胺, 99.0-100.5% (titration)
Sigma-Aldrich
铁, powder, −325 mesh, 97%
Sigma-Aldrich
羰基铁, ≥97% Fe basis
Sigma-Aldrich
N -甲基- D -葡胺, ReagentPlus®, ≥99.0% (T)
Sigma-Aldrich
铁, powder, <10 μm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, puriss. p.a., carbonyl-Iron powder, low in magnesium and manganese compounds, ≥99.5% (RT)
Sigma-Aldrich
葡甲胺, meets USP testing specifications
Sigma-Aldrich
铁, flakes, ≥99.99% trace metals basis
Sigma-Aldrich
铁, nanopowder, 35-45 nm particle size, 99.5% trace metals basis
Sigma-Aldrich
铁, granular, 10-40 mesh, >99.99% trace metals basis
Sigma-Aldrich
铁, chips, 99.98% trace metals basis
Sigma-Aldrich
铁, foil, thickness 0.1 mm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, foil, thickness 0.25 mm, ≥99.99% trace metals basis
Sigma-Aldrich
铁, wire, diam. 1.0 mm, ≥99.9% trace metals basis
Supelco
胆影葡胺, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
铁, carbon coated magnetic, nanopowder, 25 nm avg. part. size, 99.5% trace metals basis
Sigma-Aldrich
铁, wire, diam. 0.5 mm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, rod, diam. 6.3 mm, 99.98% trace metals basis
铁, IRMM®, certified reference material, 0.5 mm wire
铁, foil, 300x300mm, thickness 0.1mm, hard, 99.5%
铁, foil, 0.2m coil, thickness 0.5mm, coil width 49mm, armco« soft ingot 99.8+%
铁, wire reel, 1m, diameter 0.025mm, as drawn, 99.99+%
铁, wire reel, 20m, diameter 0.125mm, hard, 99.5%
胆影葡胺, European Pharmacopoeia (EP) Reference Standard
铁, foil, 10mm disks, thickness 0.01mm, 99.85%
铁, foil, 10mm disks, thickness 0.01mm, 99.99+%
铁, foil, 10mm disks, thickness 0.020mm, 99.85%
铁, foil, 10mm disks, thickness 0.025mm, as rolled, 99.99+%
铁, foil, 10mm disks, thickness 0.025mm, hard, 99.5%

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。